DelveInsight has launched a new report on “Follicular Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Follicular Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Follicular Lymphoma Market Report:
As per the study conducted by Green et al. (2017), titled “Chromatin modifying gene mutations in follicular lymphoma,” mutation frequency of KMT2D, CREBBP, EZH2, EP300, KMT2C, HIST1H1E, ARID1A, and SMARCA4 mutation was 72%, 65%, 25%, 15%, 13%, 14%, 11%, and 1%, respectively.
As per the study conducted by Smith et al. (2015), titled “Lymphoma incidence, survival, and prevalence 2004–2014: sub-type analyses from the UK’s Hematological Malignancy Research Network,” the incidence of FL was 3.23/100,000.
Key benefits of the report:
Follicular Lymphoma market report covers a descriptive overview and comprehensive insight of the Follicular Lymphoma Epidemiology and Follicular Lymphoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Follicular Lymphoma market report provides insights on the current and emerging therapies.
Follicular Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Follicular Lymphoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Follicular Lymphoma market.
Follicular Lymphoma Overview
Follicular lymphoma is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly, and less commonly other extranodal sites of involvement.
Follicular Lymphoma Market
The dynamics of the Follicular Lymphoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Epizyme, Xynomic Pharmaceuticals, MEI Pharma, Novartis Pharmaceuticals, Innovent Biologics, and others during the forecasted period 2018-2030.
Follicular Lymphoma Pipeline Therapies and Key Companies
Tazverik (Tazemetostat): Epizyme
Abexinostat: Xynomic Pharmaceuticals
ME-401: MEI Pharma
Tisagenlec leucel: Novartis Pharmaceuticals
Parsaclisib (IBI376): Innovent Biologics
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Follicular Lymphoma Patient Share (%) Overview at a Glance
5. Follicular Lymphoma Market Overview at a Glance
6. Follicular Lymphoma Disease Background and Overview
7. Follicular Lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Follicular Lymphoma
9. Follicular Lymphoma Current Treatment and Medical Practices
10. Unmet Needs
11. Follicular Lymphoma Emerging Therapies
12. Follicular Lymphoma Market Outlook
13. Country-Wise Follicular Lymphoma Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Follicular Lymphoma Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
“Follicular Lymphoma Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Follicular Lymphoma market. A detailed picture of the Follicular Lymphoma pipeline landscape is provided, which includes the disease overview and Follicular Lymphoma treatment guidelines.
DelveInsight’s ‘Follicular Lymphoma Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Follicular Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States